Vertex Pharmaceuticals Incorporated
Vertex
VRTX · NASDAQ
Healthcare
Catalog as of September 15, 2026. Not a live market feed.
- Fiscal Year
- 2025
- Revenue
- $12B
- Assets
- $25.6B
- SEC filing
- DEF 14A
- Filed
- April 2, 2026
Executive Compensation
Compensation reported for Vertex’s named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.
Reshma Kewalramani
CEO and President
$21.1M
Reported total
- Salary
- $1,600,000
- Stock awards
- $15,002,270
- Incentives
- $4,118,640
- Option awards
- $0
- Other
- $423,351
Stuart A. Arbuckle
Former EVP & Chief Operating Officer
$10M
Reported total
- Salary
- $521,486
- Stock awards
- $9,341,927
- Incentives
- $0
- Option awards
- $0
- Other
- $132,934
Charles F. Wagner, Jr.
Evp & Chief Operating And Financial Officer
$8.2M
Reported total
- Salary
- $974,808
- Stock awards
- $5,250,817
- Incentives
- $1,965,000
- Option awards
- $0
- Other
- $51,184
Nia Tatsis
EVP & Chief Regulatory and Quality Officer
$7M
Reported total
- Salary
- $750,000
- Stock awards
- $4,900,522
- Incentives
- $1,282,163
- Option awards
- $0
- Other
- $42,235
Amit Sachdev
EVP & Chief Patient and External Affairs Officer
$6.8M
Reported total
- Salary
- $700,000
- Stock awards
- $4,900,522
- Incentives
- $1,155,420
- Option awards
- $0
- Other
- $21,301
Carmen Bozic
EVP & Chief Medical Officer
$6.6M
Reported total
- Salary
- $835,000
- Stock awards
- $4,375,531
- Incentives
- $1,378,251
- Option awards
- $0
- Other
- $57,539
Reshma Kewalramani
CEO and President
$21.1M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A Summary Compensation Table, filed April 2, 2026.
- Salary
- $1.6M
- Stock Awards
- $15M
- Incentives
- $4.1M
- Other
- $423K
Historical Compensation
Reshma Kewalramani total compensation, fiscal years 2023–2025.
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $1,600,000 | $15,002,270 | $21,144,261 |
| 2024 | $1,541,154 | $15,002,202 | $21,538,668 |
| 2023 | $1,500,000 | $15,001,894 | $20,594,441 |
Named Executive Officers
Reshma Kewalramani
CEO and President
Vertex · VRTX
$21.1M
FY 2025 · DEF 14A
Charles F. Wagner, Jr.
Evp & Chief Operating And Financial Officer
Vertex · VRTX
$8.2M
FY 2025 · DEF 14A
Carmen Bozic
EVP & Chief Medical Officer
Vertex · VRTX
$6.6M
FY 2025 · DEF 14A
Amit Sachdev
EVP & Chief Patient and External Affairs Officer
Vertex · VRTX
$6.8M
FY 2025 · DEF 14A
Nia Tatsis
EVP & Chief Regulatory and Quality Officer
Vertex · VRTX
$7M
FY 2025 · DEF 14A
Stuart A. Arbuckle
Former EVP & Chief Operating Officer
Vertex · VRTX
$10M
FY 2025 · DEF 14A
Source information
- Company
- Vertex Pharmaceuticals Incorporated
- Ticker
- VRTX · NASDAQ
- Filing type
- DEF 14A
- Fiscal year
- 2025
- Filing date
- April 2, 2026
- SEC accession number
- 0000875320-26-000153
Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing
Related Companies
Johnson & Johnson
JNJ · NYSE
Joaquin Duato
Chairman/CEO
$32.8M
FY 2025 reported total
View company
UnitedHealth
UnitedHealth Group Incorporated
UNH · NYSE
Stephen Hemsley
Chief Executive Officer
$60.9M
FY 2025 reported total
View company
AbbVie
AbbVie Inc.
ABBV · NYSE
Robert A. Michael
Chairman Of The Board And Chief Executive Officer
$32.5M
FY 2025 reported total
View company
Abbott
Abbott Laboratories
ABT · NYSE
Robert B. Ford
Chairman Of The Board And Chief Executive Officer
$24.2M
FY 2025 reported total
View company